Related Experiment Video
Updated: Jun 27, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Novel therapeutic strategies for rare mutations in non-small cell lung cancer
Qitao Gou1, Qiheng Gou2, Xiaochuan Gan3
1Department of Radiation Oncology and Department of Head & Neck Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Abstract:
Lung cancer is still the leading cause of cancer-related mortality. Over the past two decades, the management of non-small cell lung cancer (NSCLC) has undergone a significant revolution. Since the first identification of activating mutations in the epidermal growth factor receptor (EGFR) gene in 2004, several genetic aberrations, such as anaplastic lymphoma kinase rearrangements (ALK), neurotrophic tropomyosin receptor kinase (NTRK) and hepatocyte growth factor receptor (MET), have been found. With the development of gene sequencing technology, the development of targeted drugs for rare mutations, such as multikinase inhibitors, has provided new strategies for treating lung cancer patients with rare mutations. Patients who harbor this type of oncologic driver might acquire a greater survival benefit from the use of targeted therapy than from the use of chemotherapy and immunotherapy. To date, more new agents and regimens can achieve satisfactory results in patients with NSCLC. In this review, we focus on recent advances and highlight the new approval of molecular targeted therapy for NSCLC patients with rare oncologic drivers.
Insights
Molecular targeted therapy offers new hope for non-small cell lung cancer (NSCLC) patients with rare genetic mutations. These targeted drugs provide survival benefits over traditional chemotherapy and immunotherapy for specific oncologic drivers.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality globally.
- Advances in molecular profiling have identified numerous genetic aberrations driving NSCLC.
- Targeted therapies have revolutionized NSCLC treatment paradigms.
Purpose of the Study:
- To review recent advancements in molecular targeted therapy for NSCLC.
- To highlight newly approved agents for rare oncologic drivers in NSCLC.
- To discuss the efficacy of targeted therapy compared to chemotherapy and immunotherapy.
Main Methods:
- Review of recent scientific literature and clinical trial data.
- Focus on gene sequencing technologies and identification of rare mutations.
- Analysis of approved molecular targeted therapies and their clinical outcomes.
Main Results:
- Identification of key genetic aberrations including EGFR, ALK, NTRK, and MET.
- Development of targeted drugs, such as multikinase inhibitors, for rare mutations.
- Demonstrated survival benefits of targeted therapy in patients with specific oncologic drivers.
Conclusions:
- Molecular targeted therapy represents a significant advancement in NSCLC management.
- Targeted agents offer improved outcomes for patients with rare genetic drivers.
- Continued research and development are crucial for expanding targeted treatment options.
More Related Videos
11:15Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers